Results 251 to 260 of about 1,949,102 (353)

Pharmaceutical Studies on Chinese Drug "Wuzhang".I : On the Seasonal Variation of Essential Oil in Lindera Umbellata THUNB

, 1966
Mitsuji Furuhata, Teijiro Horiguchi, Masahide Kato   +2 more
openalex   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Mapping the therapeutic versatility of WHO essential medicines: a systematic analysis of off-label indications. [PDF]

Ther Adv Drug Saf
Kateel R, Hegde S, Holla S.
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Systematic identification of cancer-type-specific drugs based on essential genes and validations in lung adenocarcinoma

Xiang Lian, Xia Kuang, Dongdong Zhang, Qian Xu, Anqiang Ye, Chengyu Wang, Hongtu Cui, Haixia Guo, Jiyun Zhang, Yuan Liu, Ge‐Fei Hao, Zhenshun Cheng, Fengbiao Guo   +12 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Additional file 2: of A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle

, 2018
Scott E. Martin, Abhilash I. Chiramel, Marie Luisa Schmidt, Yu‐Chi Chen, Nadia Whitt, Ari Watt, Eric C. Dunham, Kyle Shifflett, Shelby Traeger, Anne Leske, Eugen Buehler, Cynthia Martellaro, Janine Brandt, Lisa Wendt, Andreas MĂźller, Stephanie Peitsch, Sonja M. Best, JĂźrgen Stech, Stefan Finke, Angela RĂśmer-OberdĂśrfer, Allison Groseth, Heinz Feldmann, Thomas Hoenen   +22 more
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Cardiovascular impacts of combination cancer therapies in Africa: challenges and solutions. [PDF]

Cardiooncology
Fatokun BS, Okorobe PM, Bolarin OL, Onyegiri CU, Ezeagu CJ, Charles-Ugwuagbo IC, Ogunniyi TJ.   +6 more
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source